Project Details
Description
A Phase 2/3 Study Investigation the Phamacokinetics, Safety and Efficacy of Dupilumab in Patients ages >6 months to <6 years with Severe Atopic Dermatitis
| Status | Finished |
|---|---|
| Effective start/end date | 2/1/17 → 2/28/23 |
Funding
- REGENERON PHARMACEUTICALS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.